Geron Corporation (NASDAQ: GERN) announced today that the company received a verbal notice from the FDA that Geron’s Investigational New Drug (IND) submission for GRNOPC1, its cell therapy for spinal cord injury, has been placed on clinical hold. This is an order that the FDA issues to a company to delay a proposed trial or to suspend an ongoing investigation.
As the company has not seen the reasons for the hold in writing via a letter, it is unable to comment specifically. The company said in the release that it has been in communications with the FDA for 4 years leading to its filing.
NASDAQ halted trading of the stock at 14:30:29 pending news, so it is now not trading. Shares did manage to trade down almost 4% to $4.71 before this halt took effect. Geron’s market cap was almost $367 million before the halt, and its 52-week trading range was $3.97 to $9.85.
Jon C. Ogg
May 14, 2008
It’s Your Money, Your Future—Own It (sponsor)
Are you ahead, or behind on retirement? For families with more than $500,000 saved for retirement, finding a financial advisor who puts your interest first can be the difference, and today it’s easier than ever. SmartAsset’s free tool matches you with up to three fiduciary financial advisors who serve your area in minutes. Each advisor has been carefully vetted and must act in your best interests. Start your search now.
If you’ve saved and built a substantial nest egg for you and your family, don’t delay; get started right here and help your retirement dreams become a retirement reality.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.